PURPOSE Patients with acute myeloid leukemia (AML) in remission remain at risk for
relapse even after allogeneic hematopoietic cell transplantation (alloHCT). AML measurable …

New techniques for single-cell analysis have led to insights into hematopoiesis and the immune
system, but the ability of these techniques to cross-validate and reproducibly identify the …

Importance Preventing relapse for adults with acute myeloid leukemia (AML) in first remission
is the most common indication for allogeneic hematopoietic cell transplant. The presence …

Several prospective randomized trials comparing conditioning intensity before allogeneic
hematopoietic cell transplantation (HCT) have been performed, with conflicting results. …

Background The powerful ‘graft versus leukemia’effect thought partly responsible for the
therapeutic effect of allogeneic hematopoietic cell transplantation in acute myeloid leukemia (…

Successful clinical remission to therapy for acute myeloid leukemia (AML) is required for
long-term survival to be achieved. Despite trends in improved survival due to better supportive …

This study offers a proof of principle of patient-personalized customized single-cell
proteogenomics in AML including whole-genome sequencing–defined structural variants, currently …

Acute myeloid leukemia (AML) is a genetically heterogeneous disease that is characterized
by abnormal clonal proliferation of myeloid progenitor cells found predominantly within the …

Response criteria for patients treated for acute myeloid leukemia (AML) based on cytomorphology
are inadequate. Many patients achieving a complete remission by such criteria will …

PURPOSE Patients with myelodysplastic syndrome (MDS) are at risk of relapse after
allogeneic hematopoietic cell transplantation. The utility of ultra-deep genomic testing to predict …